Cell And Gene Therapy Manufacturing

  1. Optimize Cell Isolation And Activation For Flexibility And Scalability 11/13/2023

    Learn about a first-of-its-kind platform technology that enables isolation and activation of T cells in one step using an active release mechanism for clinical trial or commercial manufacturing.

  2. Driving Down COGS Audience Q&A 8/18/2023

    Expert panelists provide detailed answers to questions submitted in real time by our registrants providing insightful responses regarding analytical challenges to automation, test automation, and more.

  3. Dr. Peter Marks Talks a Standardized Playbook for Gene Therapy Manufacturing 1/30/2024

    In this segment, Dr. Peter Marks shares developments in CMC for advanced therapies in the near future.

  4. Process Liquids And Buffers Offering 5/2/2024

    Whether you are a researcher, scientist, or industry professional, this video will provide valuable insights into our large volume liquids manufacturing capabilities.

  5. Race To The Regulatory Finish Line: Dr. Nicole Verdun Talks Efficiencies In Platform Technologies 1/30/2024

    Could a platform approach help certain therapies make their way over the regulatory finish line more efficiently?

  6. 2024 Regulatory Outlook With Dr. Peter Marks And Dr. Nicole Verdun | Audience Q&A 1/30/2024

    Experts on the Cell & Gene Live event, 2024 Regulatory Outlook, answer questions about topics including pediatric development in rare diseases, diversity planning for ultra-rare disease, anticipated approvals by 2025, and more.

  7. Regulatory Compliance And Viral Vectors 11/13/2023

    Hear from experts who detail the specific regulatory challenges for advanced therapies, as well as how the regulatory requirements differ in early research and development in academia and in industrial vector production.

  8. Why Clinical Requirements Change: Dr. Peter Marks on Pre-IND Meeting Pathways 1/30/2024

    Learn how clinical requirements change after the FDA and a company agree on a pathway during a pre-IND meeting and how the company might recover as a result.

  9. Autoimmune Disease Research's Impact On The Development Of Cell Therapies For Oncology 5/6/2024

    Recently, many cell therapy companies have been pivoting to autoimmune diseases. Expert panelists discuss whether they think there are any learnings or potential headwinds these pivots could provide to cell therapies for oncology.

  10. Genentech, Myeloid's Approaches To mRNA Technologies 1/29/2024

    Experts at a Cell & Gene Live event discussed the use of mRNA technology in cancer immunotherapy, including a brief overview of the different approaches being used to leverage mRNA technology.